Expert Review of Clinical Pharmacology

Papers
(The H4-Index of Expert Review of Clinical Pharmacology is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments66
Personalizing tamoxifen therapy in adjuvant therapy: a brief summary of the ongoing discussion44
Renin angiotensin aldosterone inhibitors in the treatment of proteinuria in children with congenital anomalies of the kidney and urinary tract: more evidence needed40
Reducing the risk of death – a possible outcome in COPD patients36
Why is diagnosis, investigation, and improved management of kidney stone disease important? Non-pharmacological and pharmacological treatments for nephrolithiasis32
Therapeutic drug monitoring of antiretroviral therapy: current progresses and future directions32
Clinical pharmacology of antiplatelet drugs32
Sodium-glucose cotransporter 2 inhibitors in frail, older people with type 2 diabetes and heart failure: do we have enough evidence to confidently support the use?32
Risk of new onset diabetes mellitus with pitavastatin as compared to atorvastatin and rosuvastatin: a systematic review and meta-analysis31
Prostate cancer and novel pharmacological treatment options–what’s new for 2022?30
Effects of the augmentation with quetiapine or olanzapine on the metabolism of duloxetine: a retrospective analysis30
Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome27
Management of polypharmacy through deprescribing in older patients: a review of the role of AI tools27
A review of current and emerging therapies in breast cancer: implications for older adults26
JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review25
Practical considerations and emerging approaches for the management of vasomotor and sexual symptoms in breast cancer patients on endocrine therapies25
What is the potential for abuse of lisdexamfetamine in adults? A preclinical and clinical literature review and expert opinion25
Sparsentan: a dual endothelin and angiotensin II receptor antagonist approved for IgA nephropathy25
Fetal safety of medications used in treating infertility23
Amylin analogs for the treatment of obesity without diabetes: present and future23
Role of tenecteplase in ischemic stroke after 4.5 hours: an evaluation of the TRACE-III trial22
Clinical efficacy and safety of topical difamilast in the treatment of patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials22
0.25975203514099